David A. Weber, Ph.D.
Chief Executive Officer, President and Board Member
David A. Weber, Ph.D. has served as our President and Chief Executive Officer and on our board of directors since November 2010. Prior to joining us, Dr. Weber served from February 2004 to April 2010 as the Chief Executive Officer of MacuSight, Inc., a developer of a sustained delivery formulation of sirolimus for the treatment of severe ophthalmic diseases. Prior to MacuSight, Dr. Weber served as acting Chief Executive Officer and Executive Vice President of Oculex Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of intraocular pharmaceuticals and drug delivery systems, until its acquisition by Allergan in 2003. Dr. Weber has also held management positions with Oral-B Laboratories, a developer and manufacturer of oral hygiene products, and with Procter & Gamble, Co., a consumer products company. Dr. Weber received his Ph.D. in medical microbiology from Creighton University and his Master’s and Bachelor’s degrees in biological sciences from Wichita State University.
Kathie M. Bishop, Ph.D.
Chief Scientific Officer
Kathie M. Bishop, Ph.D., was appointed as our Chief Scientific Officer in November 2016 and joined the company beginning in January 2017. Dr. Bishop is a neuroscientist with more than fifteen years of pharmaceutical development experience. Prior to Otonomy she served as Chief Scientific Officer of Tioga Pharmaceuticals from May 2015 to November 2016. From September 2009 to April 2015, she served in various product development management roles at Ionis Pharmaceuticals including Vice President, Clinical Development. At Ionis, she led translational research and development of multiple preclinical and clinical programs in the neurology franchise including SPINRAZA™ (nusinersen), an approved treatment for patients with spinal muscular atrophy that was awarded the Prix Galien USA Award for the Best Biotechnology Product in 2017. From August 2001 to September 2009, Dr. Bishop served in research and development leadership roles at Ceregene, a company focused on the development of gene therapy products for the treatment of neurodegenerative disorders and retinal diseases. From September 1997 to July 2001, she worked as a post-doctoral fellow in the Molecular Neurobiology Lab at the Salk Institute for Biological Studies. Dr. Bishop obtained a Ph.D. in Neuroscience from the University of Alberta and Bachelor’s degrees in Cell Biology and Genetics from the University of British Columbia and Psychology from Simon Fraser University.
Paul E. Cayer
Chief Financial & Business Officer
Paul E. Cayer has served as our Chief Business Officer since October 2008 and Chief Financial Officer since October 2010. Mr. Cayer brings more than 25 years of experience in the pharmaceutical, medical device and healthcare technology field. Prior to joining our company, Mr. Cayer served from 2005 to 2008 as Senior Vice President, Corporate Development for Verus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of allergic and respiratory disorders in children. From 2001 to 2005, Mr. Cayer served as the Chief Financial Officer and Senior Vice President, Business Development of Targeted Molecules Corporation, a biopharmaceutical company. Mr. Cayer has also held various management positions with Gensia Pharmaceuticals, Inc., a biopharmaceutical company, Acuson, a provider of medical ultrasound systems, Castle & Cooke, a consumer products company, and served as consultant with Booz-Allen & Hamilton, a management and technology consulting firm. Mr. Cayer received his MBA and Bachelor’s degree in biomechanical engineering from Harvard University.
Robert Michael Savel, II
Chief Technical Officer
Robert Michael Savel, II has served as our Chief Technical Officer since January 2014. From September 2011 to December 2013, Mr. Savel served as General Manager and Senior Vice President of Operations for Optimer Pharmaceuticals, Inc., a biopharmaceuticals company. From September 2010 to June 2011, Mr. Savel served as Senior Vice President and Chief Technical Officer for Inspire Pharmaceuticals, Inc., an ophthalmic pharmaceutical company. From April 2008 to September 2010, Mr. Savel served as President of Savel Enterprises LLC, a management consulting firm. From April 2007 to April 2008, Mr. Savel served as the Senior Vice President of Technical Operations for PDL BioPharma, an antibody manufacturer. Earlier in his career, he held leadership operating positions with Johnson & Johnson, a medical devices, pharmaceutical and consumer packaged goods manufacturer, which included the position of Vice President, Quality and Compliance. Mr. Savel received his Bachelor’s degree in mechanical engineering from Virginia Polytechnic Institute and State University in Blacksburg, Virginia.